CLARK COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 16 cases of invasive cancer were diagnosed among Clark County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Clark County and the State of Idaho. 2017–2021

Cancer Incidence 2017–2021	Clark County	State of Idaho
All Sites/Types	16	47,333
Female Breast	2	6,943
Prostate	1	6,766
Lung & Bronchus	1	4,959
Colorectal	0	3,632

Table 3 (Cancer Incidence 2017–2021, Comparison between Clark County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Clark County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Clark County was 380.4 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (526.5) gives an estimate of the relative burden of disease in Clark County.

The age- and sex-adjusted incidence rate of invasive cancer in Clark County, all sites combined, was 349.9 cases per 100,000 persons per year during 2017–2021. There were fewer cases of cancer in Clark County (16) than expected (24.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 6 Clark County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Clark County and the State of Idaho, 2018–2022

Mortality 2018–2022	Clark County	State of Idaho
All Deaths	30	80,538
Cancer Deaths	6	15,233
% of All Deaths	20.0%	18.9%
Lung & Bronchus	0	2,937
Colorectal	0	1,332
Pancreas	1	1,190
Female Breast	0	1,111
Prostate	0	997

Table 4 (Cancer Mortality 2018–2022, Comparison between Clark County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Clark County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Clark County, all sites combined, was 123.1 deaths per 100,000 persons per year during 2018–2022, compared with 165.4 for the remainder of the state. There were fewer cancer deaths in Clark County (6) than expected (8.1) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. **Data Note:** Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021 COMPARISON BETWEEN CLARK COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Clark County						Remainder of Idaho			
Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude	
Site/Type	Sex	Cases	Years	Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases	Years	Rate (1)	
All Sites Combined	Total	16	4,206	380.4	349.9	24.1	0.109	47,317	8,987,900	526.5	
All Sites Combined All Sites Combined	Male Female	7 9	2,173 2,033	322.1 442.7	270.9 440.5	14.5 10.1	0.049 << 0.900	25,263 22,054	4,510,100 4,477,800	560.1 492.5	
Bladder	Total	-	4,206	-	-	1.2	0.613	2,220	8,987,900	24.7	
Bladder	Male	-	2,173	-	-	1.1	0.679	1,773	4,510,100	39.3	
Bladder	Female Total	-	2,033 4,206	-	-	0.2	1.000 1.000	447 657	4,477,800	10.0 7.3	
Brain - malignant Brain - malignant	Male	-	2,173	-	_	0.3	1.000	382	8,987,900 4,510,100	7.3 8.5	
Brain - malignant	Female	-	2,033	-	-	0.1	1.000	275	4,477,800	6.1	
Brain and other CNS - non-malignant	Total	-	4,206	-	-	0.8	0.911	1,547	8,987,900	17.2	
Brain and other CNS - non-malignant Brain and other CNS - non-malignant	Male Female	-	2,173 2,033	-	_	0.3 0.5	1.000 1.000	500 1,047	4,510,100 4,477,800	11.1 23.4	
Breast	Total	2	4,206	47.6	44.7	3.5	0.646	7,006	8,987,900	77.9	
Breast	Male	-	2,173	-	-	0.0	1.000	65	4,510,100	1.4	
Breast in city	Female	2	2,033 4,206	98.4	99.1	3.1	0.790 1.000	6,941 1,369	4,477,800	155.0 15.2	
Breast - in situ Breast - in situ	Total Male	-	2,173	-	_	0.7 0.0	1.000	1,309	8,987,900 4,510,100	0.1	
Breast - in situ	Female	-	2,033	-	-	0.6	1.000	1,365	4,477,800	30.5	
Cervix	Female	-	2,033	-	-	0.1	1.000	294	4,477,800	6.6	
Colorectal Colorectal	Total Male	-	4,206 2,173	-	-	1.9 1.1	0.306 0.642	3,632 1,977	8,987,900 4,510,100	40.4 43.8	
Colorectal	riviale Female	-	2,173	_		0.8	0.642	1,977	4,510,100	43.8 37.0	
Corpus Uteri	Female	2	2,033	98.4	100.9	0.6	0.243	1,352	4,477,800	30.2	
Esophagus	Total	-	4,206	-	-	0.3	1.000	507	8,987,900	5.6	
Esophagus Esophagus	Male Female	-	2,173 2,033	-	-	0.3 0.0	1.000 1.000	429 78	4,510,100 4,477,800	9.5 1.7	
Hodgkin Lymphoma	Total	-	4,206	-	-	0.0	1.000	222	8,987,900	2.5	
Hodgkin Lymphoma	Male	-	2,173	-	-	0.1	1.000	129	4,510,100	2.9	
Hodgkin Lymphoma	Female	-	2,033	-	-	0.0	1.000	93	4,477,800	2.1	
Kidney and Renal Pelvis	Total Male	-	4,206 2,173	-	-	1.0 0.7	0.746 0.959	1,951 1,310	8,987,900 4,510,100	21.7 29.0	
Kidney and Renal Pelvis Kidney and Renal Pelvis	Female	-	2,173	-	-	0.7	1.000	641	4,477,800	14.3	
Larynx	Total	-	4,206	-	-	0.1	1.000	220	8,987,900	2.4	
Larynx	Male	-	2,173	-	-	0.1	1.000	167	4,510,100	3.7	
Larynx Leukemia	Female Total	- 1	2,033 4,206	23.8	- 21.5	0.0	1.000 1.000	53 1,726	4,477,800 8,987,900	1.2 19.2	
Leukemia	Male	_ '	2,173	23.0	- 21.3	0.9	1.000	1,720	4,510,100	23.0	
Leukemia	Female	1	2,033	49.2	47.8	0.3	0.551	690	4,477,800	15.4	
Liver and Bile Duct	Total	-	4,206	•	-	0.4	1.000	843	8,987,900	9.4	
Liver and Bile Duct Liver and Bile Duct	Male Female	-	2,173 2,033	-	-	0.3 0.1	1.000 1.000	594 249	4,510,100 4,477,800	13.2 5.6	
Lung and Bronchus	Total	1	4,206	23.8	21.3	2.6	0.539	4,958	8,987,900	55.2	
Lung and Bronchus	Male	1	2,173	46.0	37.7	1.5	1.000	2,494	4,510,100	55.3	
Lung and Bronchus	Female	-	2,033	-	-	1.1	0.638	2,464	4,477,800	55.0	
Melanoma of the Skin Melanoma of the Skin	Total Male	2 2	4,206 2,173	47.6 92.0	43.8 76.5	1.6 1.1	0.947 0.600	3,142 1,893	8,987,900 4,510,100	35.0 42.0	
Melanoma of the Skin	Female	-	2,033	-	-	0.6	1.000	1,249	4,477,800	27.9	
Myeloma	Total	1	4,206	23.8	21.4	0.4	0.630	727	8,987,900	8.1	
Myeloma	Male	1	2,173	46.0	37.4	0.3	0.464	446		9.9	
Myeloma Non-Hodgkin Lymphoma	Female Total	- 2	2,033 4,206	47.6	- 43.6	0.1 1.0	1.000 0.540	281 1,990	4,477,800 8,987,900	6.3 22.1	
Non-Hodgkin Lymphoma	Male	1	2,173	46.0	39.5	0.6	0.948	1,145	4,510,100	25.4	
Non-Hodgkin Lymphoma	Female	1	2,033	49.2	48.4	0.4	0.645	845	4,477,800	18.9	
Oral Cavity and Pharynx	Total		4,206	-	-	0.7	1.000	1,315	8,987,900	14.6	
Oral Cavity and Pharynx Oral Cavity and Pharynx	Male Female	-	2,173 2,033		-	0.5 0.2	1.000 1.000	940 375	4,510,100 4,477,800	20.8 8.4	
Ovary	Female	-	2,033	-	-	0.2	1.000	553	4,477,800	12.3	
Pancreas	Total	1	4,206	23.8	21.2	0.8	1.000	1,487	8,987,900	16.5	
Pancreas Pancreas	Male Female	- 1	2,173 2,033	- 49.2	- 48.0	0.5 0.3	1.000 0.529	826 661	4,510,100 4,477,800	18.3 14.8	
Prostate	Male	1	2,033	46.0	39.7	3.8	0.329	6,765	4,510,100	150.0	
Stomach	Total	1	4,206	23.8	21.3	0.2	0.439	473	8,987,900	5.3	
Stomach	Male	- ,	2,173	-		0.2	1.000	307	4,510,100	6.8	
Stomach	Female	1	2,033	49.2	47.3	0.1	0.151	166 274	4,477,800	3.7 6.1	
Testis Thyroid	Male Total	<u> </u>	2,173 4,206	23.8	23.4	0.1 0.6	1.000 0.861	1,184	4,510,100 8,987,900	13.2	
Thyroid	Male	_ '	2,173	-	-	0.0	1.000	372	4,510,100	8.2	
Thyroid	Female	1	2,033	49.2	50.2	0.4	0.607	812	4,477,800	18.1	
Pediatric Age 0 to 19	Total	-	1,123	-	-	0.2	1.000	425	2,498,201	17.0	
Pediatric Age 0 to 19	Male	-	538	-	-	0.1	1.000	214	1,273,783	16.8	
Pediatric Age 0 to 19	Female	re everessed as t	585	-	-	0.1	1.000	211	1,224,418	17.2	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

^{2.} Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

^{3.} Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

^{4.} P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

[&]quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

TABLE 4: CANCER MORTALITY 2018–2022 COMPARISON BETWEEN CLARK COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Clark County						Remainder of Idaho			
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude	
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)	
All Causes of Death	Total	30	4,134	725.7	583.9	44.9	0.024 <<	80,505	9,207,260	874.4	
All Causes of Death	Male	14	2,144	653.0	480.1	27.0	0.009 <<	42,772	4,625,553	924.7	
All Causes of Death	Female	16	1,990	804.0	707.2	18.6	0.642	37,733	4,581,707	823.6	
All Malignant Cancers	Total	6	4,134	145.1	123.1	8.1	0.612	15,227	9,207,260	165.4	
All Malignant Cancers	Male	1 5	2,144 1,990	46.6	35.6	5.0 3.3	0.080 0.460	8,234 6,993	4,625,553 4,581,707	178.0 152.6	
All Malignant Cancers Bladder	Female Total	- -	4,134	251.3	234.1	0.3	1.000	485	9,207,260	5.3	
Bladder	Male	_	2,144	_	_	0.3	1.000	375	4,625,553	8.1	
Bladder	Female	_	1,990	_	_	0.1	1.000	110	4,581,707	2.4	
Brain and Other Nervous System	Total	-	4,134	-	-	0.3	1.000	518	9,207,260	5.6	
Brain and Other Nervous System	Male	-	2,144	-	-	0.2	1.000	289	4,625,553	6.2	
Brain and Other Nervous System	Female	-	1,990	-	-	0.1	1.000	229	4,581,707	5.0	
Breast	Total	-	4,134	-	-	0.6	1.000	1,124	9,207,260	12.2	
Breast	Male	-	2,144	-	-	0.0	1.000	13	4,625,553	0.3	
Breast Cervix	Female Female	-	1,990 1,990	-	-	0.5 0.0	1.000 1.000	1,111 88	4,581,707 4,581,707	24.2 1.9	
Colorectal	Total		4,134	-	-	0.0	0.988	1,332	9,207,260	14.5	
Colorectal	Male	_	2,144	-	-	0.7	1.000	732	4,625,553	15.8	
Colorectal	Female	-	1,990	-	-	0.3	1.000	600	4,581,707	13.1	
Corpus Uteri	Female	-	1,990	-	-	0.1	1.000	169	4,581,707	3.7	
Esophagus	Total	-	4,134	-	-	0.2	1.000	461	9,207,260	5.0	
Esophagus	Male	-	2,144	-	-	0.2	1.000	391	4,625,553	8.5	
Esophagus	Female	-	1,990	-	-	0.0	1.000	70	4,581,707	1.5	
Hodgkin Lymphoma	Total	-	4,134	-	-	0.0	1.000	25	9,207,260	0.3	
Hodgkin Lymphoma	Male Female	-	2,144 1,990	-	-	0.0 0.0	1.000 1.000	14 11	4,625,553 4,581,707	0.3 0.2	
Hodgkin Lymphoma Kidney	Total	- 1	4,134	24.2	20.5	0.0	0.369	385	9,207,260	4.2	
Kidney	Male	1	2,144	46.6	36.3	0.1	0.303	245	4,625,553	5.3	
Kidney	Female	_ '	1,990	-	-	0.1	1.000	140	4,581,707	3.1	
Larynx	Total	-	4,134	-	-	0.0	1.000	76	9,207,260	0.8	
Larynx	Male	-	2,144	-	-	0.0	1.000	65	4,625,553	1.4	
Larynx	Female	-	1,990	-	-	0.0	1.000	11	4,581,707	0.2	
Leukemia	Total	-	4,134	-	-	0.4	1.000	665	9,207,260	7.2	
Leukemia	Male	-	2,144	-	-	0.2	1.000	397	4,625,553	8.6	
Leukemia Liver and Bile Duct	Female Total	-	1,990 4,134	-	-	0.1 0.3	1.000 1.000	268 635	4,581,707 9,207,260	5.8 6.9	
Liver and Bile Duct	Male	-	2,144	-	-	0.3	1.000	423	4,625,553	9.1	
Liver and Bile Duct	Female	_	1,990	_	_	0.2	1.000	212	4,581,707	4.6	
Lung and Bronchus	Total	-	4,134	-	-	1.5	0.431	2,937	9,207,260	31.9	
Lung and Bronchus	Male	-	2,144	-	-	0.9	0.807	1,541	4,625,553	33.3	
Lung and Bronchus	Female	-	1,990	-	-	0.6	1.000	1,396	4,581,707	30.5	
Melanoma of the Skin	Total	-	4,134	-	-	0.2	1.000	301	9,207,260	3.3	
Melanoma of the Skin	Male	-	2,144	-	-	0.1	1.000	200	4,625,553	4.3	
Melanoma of the Skin	Female	-	1,990	-	-	0.0	1.000	101	4,581,707	2.2	
Myeloma Myeloma	Total Male	-	4,134 2,144	-	-	0.2 0.1	1.000 1.000	325 188	9,207,260 4,625,553	3.5 4.1	
Myeloma	Female	-	2,144 1,990	-	-	0.1	1.000	137	4,581,707	3.0	
Non-Hodgkin Lymphoma	Total		4,134		_	0.1	1.000	568	9,207,260	6.2	
Non-Hodgkin Lymphoma	Male	_	2,144	-	_	0.2	1.000	310	4,625,553	6.7	
Non-Hodgkin Lymphoma	Female	-	1,990	-	-	0.1	1.000	258	4,581,707	5.6	
Oral Cavity and Pharynx	Total	-	4,134	-	-	0.1	1.000	275	9,207,260	3.0	
Oral Cavity and Pharynx	Male	-	2,144	-	-	0.1	1.000	192	4,625,553	4.2	
Oral Cavity and Pharynx	Female	-	1,990	-	-	0.0	1.000	83	4,581,707	1.8	
Ovary	Female	- 1	1,990	- 24.0	-	0.2	1.000	361	4,581,707	7.9	
Pancreas Pancreas	Total Male	1	4,134 2,144	24.2	21.1	0.6	0.915 1.000	1,189 650	9,207,260 4,625,553	12.9 14.1	
Pancreas Pancreas	riviale Female	- 1	2,144 1,990	50.3	- 47.4	0.4 0.2	0.440	650 539	4,581,707	14.1	
Prostate	Male	_ '	2,144	-		0.2	1.000	997	4,625,553	21.6	
Stomach	Total	1	4,134	24.2	20.4	0.1	0.195	193	9,207,260	2.1	
Stomach	Male	- '	2,144	-	-	0.1	1.000	119	4,625,553	2.6	
Stomach	Female	1	1,990	50.3	46.7	0.0	0.068	74	4,581,707	1.6	
			ie number of cases i						, ,		

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

^{2.} Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

^{3.} Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

^{4.} P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

	State of								Clark
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care									
Have Health Insurance, Age < 65 (2021–2022)	90.0%	89.3%	87.8%	86.4%	92.6%	87.2%	89.1%	92.6%	
Not See Doctor Due to Cost in Past Year (2020–2022)	10.4%	9.5%	11.0%	11.0%	10.2%	10.2%	10.4%	11.3%	
Cancer Screening									
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years)	62.9%	61.0%	70.0%	60.3%	66.1%	58.9%	61.0%	62.5%	
Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020)	71.1%	73.7%	73.6%	70.9%	72.9%	69.4%	69.3%	65.5%	
Colorectal Cancer Screening, Age 45–75 (2022)	63.3%	61.0%	62.5%	60.8%	67.2%	65.0%	60.4%	60.2%	
Tobacco Use									
Current Tobacco User (2020–2022)	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	
Other Cancer-Related \									
Healthy Weight by Body Mass Index, Age 20+ (2020–2022)	30.0%	30.0%	30.1%	26.5%	33.7%	27.5%	26.7%	30.2%	
Any Physical Activity Besides Job Past 30 Days (2018–2022)	79.1%	79.0%	78.0%	75.4%	82.7%	75.2%	76.7%	81.0%	
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	22.0%	22.8%	19.2%	20.0%	25.2%	19.5%	20.4%	20.3%	
Home Ever Tested for Radon (2016, 2018, 2020)	22.9%	30.8%	18.3%	16.9%	25.2%	20.1%	23.0%	21.0%	

Access to Care

Have Health Insurance – 2021–2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year - 2020-2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

Pap Test - 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

<u>Colorectal Cancer Screening</u> – 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Cancer Screening and Risk Factors

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.



